How can we reduce the cost of our viral vector manufacturing, specifically our plasmid DNA costs?
This question is part of the following Ask The Expert session:
Plasmid DNA Production for Cell and Gene Therapy
Job Title: Associate Director, EMEA Segment Development for Cell and Gene Therapy
Several parameters can affect the costs for viral vector manufacturing, such as the choice of cell line (adherent versus suspension) and the process strategy (single-use versus multi-use solutions). Data suggest that the upstream costs can be lowered by up to 57% when opting for suspension culture versus adherent cultures. Single-use solutions eliminate the need for cleaning and cleaning validation and allow for higher flexibility and increased manufacturing capacity.
Cost reduction for pDNA manufacturing specifically, can be realized by efficient downstream processing and the incorporation of single-use solutions. Product recommendations to obtain a high yield during downstream processing are discussed in question 5.